An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Twenty six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an
open label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and
Letter-Number Sequencing subtests of the Wechsler Memory Scale III (Third edition) and the
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures
attention, language, visuospatial skills, and immediate and delayed memories. The Clinician
Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale
(HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan
Disability Scale (SDS) were used to assess improvement in PTSD symptoms, as secondary outcome
measures.